<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Apap Mangion S</submitter><funding>Rosetrees Trust</funding><funding>Multiple Sclerosis Society - UK</funding><funding>National Multiple Sclerosis Society - US</funding><funding>National Institute for Health and Care Research</funding><pagination>e71101</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12657254</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>People with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9-hole peg test (9HPT) is the primary clinical measure for ULD but does not fully capture the patient experience. The ABILHAND-23 is a well-validated patient-reported outcome measure (PROM) that evaluates bimanual ability in daily function. However, no large-scale studies have assessed if the 9HPT reflects the individual ULD experience in pwPMS.&lt;h4>Objectives&lt;/h4>We sought to (van Munster et al. 2023) assess the associations between the ABILHAND-23 and 9HPT, and (Huertas-Hoyas et al. 2020) to assess the ability of the 9HPT and other relevant covariables to predict ABILHAND-23 scores, using baseline</pubmed_abstract><journal>Brain and behavior</journal><pubmed_title>The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test.</pubmed_title><pmcid>PMC12657254</pmcid><funding_grant_id>HTA Project: 15/57/143</funding_grant_id><pubmed_authors>Nicholas J</pubmed_authors><pubmed_authors>Bianchi A</pubmed_authors><pubmed_authors>Farrell R</pubmed_authors><pubmed_authors>Leibowitz M</pubmed_authors><pubmed_authors>Braisher M</pubmed_authors><pubmed_authors>Favarato G</pubmed_authors><pubmed_authors>Oraluzume O</pubmed_authors><pubmed_authors>John N</pubmed_authors><pubmed_authors>Wright S</pubmed_authors><pubmed_authors>Apap Mangion S</pubmed_authors><pubmed_authors>Blackstone J</pubmed_authors><pubmed_authors>Angelis F</pubmed_authors><pubmed_authors>Vecchio G</pubmed_authors><pubmed_authors>Calvi A</pubmed_authors><pubmed_authors>Wade C</pubmed_authors><pubmed_authors>Williams T</pubmed_authors><pubmed_authors>UCL MS‐STAT2 Investigators</pubmed_authors><pubmed_authors>Chataway J</pubmed_authors><pubmed_authors>Doshi A</pubmed_authors></additional><is_claimable>false</is_claimable><name>The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test.</name><description>&lt;h4>Background&lt;/h4>People with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9-hole peg test (9HPT) is the primary clinical measure for ULD but does not fully capture the patient experience. The ABILHAND-23 is a well-validated patient-reported outcome measure (PROM) that evaluates bimanual ability in daily function. However, no large-scale studies have assessed if the 9HPT reflects the individual ULD experience in pwPMS.&lt;h4>Objectives&lt;/h4>We sought to (van Munster et al. 2023) assess the associations between the ABILHAND-23 and 9HPT, and (Huertas-Hoyas et al. 2020) to assess the ability of the 9HPT and other relevant covariables to predict ABILHAND-23 scores, using baseline</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-05T19:55:04.191Z</modification><creation>2026-05-21T03:11:46.823Z</creation></dates><accession>S-EPMC12657254</accession><cross_references><pubmed>41299878</pubmed><doi>10.1002/brb3.71101</doi></cross_references></HashMap>